Home › Funds › Duquesne Family Office LLC › NAMS
Duquesne Family Office LLC position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
Duquesne Family Office LLC reported holding 3,357,146 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$81.6M, representing 2.17% of its reported portfolio and ranking #12 among its reported holdings. Duquesne Family Office LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Duquesne Family Office LLC's NAMS position evolved
Duquesne Family Office LLC first disclosed a stake in NAMS in Q3 2024 at 287,535 shares (US$4.8M). The position peaked in Q4 2025 at 3,070,146 shares, worth US$107.7M. Across 9 filings, Duquesne Family Office LLC increased the stake 5 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 3,357,146 shares valued at US$81.6M — an increase of 287,000 shares quarter over quarter.. Notable position changes include a 178% increase in Q1 2025 (shares fell 8% over the following quarter), a 131% increase in Q3 2025 (shares rose 23% over the following quarter), a 60% increase in Q4 2025 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 287.54K | $4.77M | New |
| Q4 2024 | 287.54K | $7.39M | Hold |
| Q1 2025 | 800.36K | $16.38M | Add |
| Q2 2025 | 832.17K | $15.07M | Add |
| Q3 2025 | 1.92M | $54.71M | Add |
| Q4 2025 | 3.07M | $107.70M | Add |
| Q1 2026 | 3.07M | $98.28M | Hold |
| Q2 2026 | 3.07M | $104.05M | Hold |
| Q3 2026 | 3.36M | $81.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 34 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$461.8M), RA CAPITAL MANAGEMENT, L.P. (US$232.3M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.99M sh · $461.81M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $232.26M · Q3 2026
- FCPM III SERVICES B.V. 8.49M sh · $206.49M · Q3 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.25M sh · $103.46M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $92.58M · Q3 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M sh · $53.07M · Q3 2026
- MAVERICK CAPITAL LTD 1.86M sh · $45.13M · Q3 2026
More on Duquesne Family Office LLC
FAQ
How long has Duquesne Family Office LLC held NAMS?
Duquesne Family Office LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Duquesne Family Office LLC's current position in NAMS?
As of Q3 2026, Duquesne Family Office LLC holds 3.36M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $81.65M, representing 2.17% of its reported portfolio and ranking #12.
Has Duquesne Family Office LLC been buying or selling NAMS?
In the latest 13F filing (Q3 2026), Duquesne Family Office LLC increased its position in NAMS. The position peaked in Q4 2025 at 3.07M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.